Scientists have discovered that the blood of western diamondback rattlesnakes contains a cocktail of natural proteins that can neutralize venom from several dangerous snake species, and in laboratory tests this mixture proved about 10 times more potent than a current commercial antivenom. The finding, published in the Proceedings of the National Academy of Sciences, points toward a new generation of snakebite treatments inspired by evolution's own design. Researchers at the University of Maryland in the United States led the study, which focused on toxin-blocking proteins that rattlesnakes evolved to protect themselves from accidental self-envenomation.
A century-old mystery finally cracked
For over 100 years, scientists knew from anecdotes that vipers tend to be resistant to their own venom, but what exactly circulated in their blood remained unclear. In 2022, the lab of Distinguished University Professor Sean B. Carroll identified one key protein, called FETUA-3, which could block many metalloproteinase toxins in western diamondback venom. Now, the team has gone further by combining specific proteins found in rattlesnake blood, achieving unusually strong protection against venom from several dangerous species.
Why snakebites still matter
Snakebite is considered one of the world's most neglected tropical diseases. The World Health Organization estimates that venomous snakes kill 80,000 to 140,000 people each year, and hundreds of thousands of survivors face permanent disabilities. Many victims live in rural areas where effective antivenom is hard to get. Current treatments are made by injecting venom into large animals and collecting their antibodies, a process that is costly, variable in quality, and can cause serious immune reactions. The new approach, using natural snake proteins, could sidestep those problems.
Carroll called the discovery "one of those great stories where nature has already solved a problem we've been grappling with for decades." The research was supported by the University of Maryland, where Carroll holds an endowed chair. While the work is still in laboratory stages, it offers a clear path toward developing more powerful and reliable antivenoms for regions where snakebites remain a daily threat.
